Overview

A Study of the Efficacy and Safety of ETC-1002 in Subjects With Statin Intolerance

Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This study will assess the LDL-C lowering efficacy and safety of ETC-1002 versus placebo in subjects with hypercholesterolemia and a history of statin intolerance.
Phase:
Phase 2
Details
Lead Sponsor:
Esperion Therapeutics
Esperion Therapeutics, Inc.
Treatments:
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid